Full-Time

Scientist/Senior Scientist

CNS Cell Biology and Light Microscopy

Posted on 6/12/2025

Altos Labs

Altos Labs

501-1,000 employees

Biotech startup advancing cellular rejuvenation therapies

Compensation Overview

$127.5k - $282k/yr

San Carlos, CA, USA

In Person

Category
Biology & Biotech (4)
, , ,
Required Skills
Computer Vision
Requirements
  • PhD in a related field, such as Cell Biology, Neuroscience, Genetics
  • Thorough understanding of the principles of light microscopy image visualization, analysis, and processing
  • Demonstrable understanding of cell metabolism, including the impact of metabolism on chromatin and cell fate
  • Excellent communication skills and proven ability to collaborate within a dynamic team.
Responsibilities
  • Provide advanced cell culture, metabolic, and genetic manipulation of iPSC-derived CNS cell types and primary CNS cells.
  • Provide independent design and implementation of all phases of light microscopy experimentation, including experimental design, microscope operation, image capture, and quantitative image analysis.
  • Engage with cross-Altos research labs to bridge in vitro with in vivo models and to suggest complementary genetic and morphological profiling approaches.
  • Stay abreast of advances in light microscopy methods and technologies so that these can be brought to Altos as needed.
  • Assist other scientists in the Frost group and beyond in quantitative analysis of microscope images using tools such as Zen, Elements, Arivis, Napari, Fiji, and other software. When appropriate, manage image analysis collaborations with the Computer Vision team.
Desired Qualifications
  • Primary CNS cell isolation and culture
  • CRISPR-based genetic manipulation of mammalian cells
  • Practical experience with the management of terabyte-size microscopy datasets
  • Literacy in MATLAB, R, or Python
  • Practical experience with cellular image segmentation tools

Altos Labs focuses on cell rejuvenation research to restore cellular health and resilience, with the aim of reversing diseases, injuries, and disabilities by programming cells to resist stressors that cause illness. It advances biotech R&D in cellular rejuvenation, producing treatments that can be commercialized for healthcare providers or patients and likely collaborates with research institutions and pharma partners. Unlike purely diagnostic firms, Altos Labs centers on developing breakthrough cellular therapies and regenerative strategies grounded in research, seeking to improve long-term health outcomes. Its goal is to translate cellular rejuvenation science into practical treatments that extend healthspan and reverse disease processes.

Company Size

501-1,000

Company Stage

Early VC

Total Funding

$3.3B

Headquarters

Los Altos, California

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • Appointed Dr. Joan Mannick as CMO to launch clinical trials.
  • $3 billion funding from Jeff Bezos enables rapid R&D scaling.
  • Acquired Stanford-rooted biotech to bolster aging-stopping pipeline.

What critics are saying

  • Calico Labs advances AI-driven programs, eroding first-mover edge.
  • FDA rejection of Rejuvenate Bio's therapy heightens scrutiny.
  • Yamanaka toxicity in primate trials forces reprogramming redesign.

What makes Altos Labs unique

  • Altos Labs pioneers cellular rejuvenation programming using Yamanaka factors.
  • Operates Institutes in San Francisco, San Diego, and Cambridge, UK.
  • Focuses on reversing disease via partial reprogramming, not full iPSCs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

1%
Longevity.Technology
Aug 5th, 2025
Is Altos Labs gearing up for clinical trials?

Longevity biotech giant Altos Labs has appointed Dr Joan Mannick as its Chief Medical Officer and head of product development, signaling a shift toward advancing clinical programs based on the company's cellular rejuvenation technology.

The Business Journals
May 21st, 2025
Jeff Bezos-backed, lifespan-focused Altos Labs buys small biotech with Stanford roots

Altos Labs, backed by $3 billion from Jeff Bezos and others, has snagged a small Peninsula company focused on one approach to stopping aging

The Spirits Business
Mar 27th, 2024
Altos is UK off-trade's leading 100% agave Tequila

In London, Altos recently launched its inaugural Margarita Masters competition for bartenders, with the hope of taking it nationwide in the future.

Startup Italia
Nov 17th, 2023
«Ad Altos Labs Vogliamo Creare Una Nuova Medicina». Simone Bianco E L’Avventura Nella Venture Californiana

«Per uno scienziato Elon Musk ha senz’altro meno appeal di un Premio Nobel». Se poi i Nobel sono quattro, tutti seduti nel board of directors della startup per cui lavori, potremmo dire non esserci partita. Tra questi, ad esempio, Jennifer Doudna, che ha vinto grazie al lavoro sull’editing genetico Crispr nel 2020. Simone Bianco, employee numero 27 di Altos Labs con sede a San Francisco, è Principal Investigator e Director of Computational Biology in quella che lui preferisce definire una venture, non una startup. Nel corso dell’intervista gli abbiamo chiesto di Musk e dei suoi piani per salvare l’umanità, anche con Neuralink, ma la discussione ha rapidamente virato verso altre figure, più specializzate nella materia in questione. Altos Labs, dunque

The Recursive
Mar 8th, 2023
Finding The Fountain Of Youth: Meet The Startups Pioneering Longevity Solutions

If technology allowed humanity to live forever in the future, would you take the ticket? We asked our readers recently and were surprised to see the balance tilt towards “No” (60% of respondents). One answer was hidden in a comment from one of our readers – they would want to live forever, yet only if they stayed young. Among others, living long worries people as it is associated with getting old and suffering from various diseases.Yet if technology allows us to extend our life spans it will also likely improve our health spans. According to demographers, children today have a better chance of living up to 100 years old than ever before. But their lives won’t be just longer, they will also benefit from day-to-day technological advances aimed at improving their well-being, preventing diseases, and keeping their minds and bodies in shape.Slowing aging presents an economic opportunity, too. In the US, an estimate shows that just one to two years increase in life expectancy are worth between $7 trillion and $38 trillion

INACTIVE